![Helen Thackray](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Helen Thackray
Corporate Officer/Principal bei
Holy Cross Hospital (Maryland)
Vermögen: 1 Mio $ am 31.05.2026
Profil
Helen M.
Thackray is currently a Member of the Institutional Review Board at Holy Cross Hospital (Maryland) and an Assistant Clinical Professor at GW School of Medicine & Health Sciences since 2000.
Former positions include Independent Director at ImmunoGen, Inc. from 2021 to 2024, Chief Research & Development Officer at BioCryst Pharmaceuticals, Inc. from 2021 to 2025, Vice President-Clinical Product Development at Biosynexus, Inc. from 2001 to 2006, Chief Medical Officer & SVP-Clinical Development at GlycoMimetics, Inc. from 2012 to 2021, and Member of the Institutional Review Board at the National Center for Health Statistics.
Education includes undergraduate studies at Stanford University and a doctorate from GW School of Medicine & Health Sciences.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.04.2026 | 161.618 ( 0,06 % ) | 1 Mio $ | 31.05.2026 |
Aktive Positionen von Helen Thackray
| Unternehmen | Position | Beginn |
|---|---|---|
Holy Cross Hospital (Maryland) | Corporate Officer/Principal | - |
Gw School of Medicine & Health Sciences
 Gw School of Medicine & Health Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.2000 |
Ehemalige bekannte Positionen von Helen Thackray
| Unternehmen | Position | Ende |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2025 |
| IMMUNOGEN, INC. | Direktor/Vorstandsmitglied | 12.02.2024 |
GlycoMimetics, Inc.
 GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Technik-/Wissenschafts-/F&E-Leiter | 19.03.2021 |
Biosynexus, Inc.
 Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Corporate Officer/Principal | 01.01.2006 |
National Center for Health Statistics
 National Center for Health Statistics General GovernmentGovernment Provides public health statistics | Corporate Officer/Principal | - |
Ausbildung von Helen Thackray
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
29
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
BioCryst Pharmaceuticals, Inc.
 BioCryst Pharmaceuticals, Inc. BiotechnologyHealth Technology Designs and develops oral small-molecule & injectable protein therapeutics | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biosynexus, Inc.
Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
GlycoMimetics, Inc.
GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Health Technology |
Holy Cross Hospital (Maryland) | Health Services |
National Center for Health Statistics
National Center for Health Statistics General GovernmentGovernment Provides public health statistics | Government |
Gw School of Medicine & Health Sciences
Gw School of Medicine & Health Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
